Home/Click Therapeutics/Austin Speier
AS

Austin Speier

Chief Strategy Officer

Click Therapeutics

Click Therapeutics Pipeline

DrugIndicationPhase
CT-152 (Rejoyn™)Major Depressive Disorder (adjunct to antidepressant medication)Phase 3
CT-132Episodic MigrainePhase 3
CT-155Negative Symptoms of SchizophreniaPhase 3
Unnamed Breast Cancer ProgramBreast CancerPilot/Phase 2